Dabigatran Etexilate 110mg

DRUG2 trials

Sponsors

Boehringer Ingelheim, Wuhan Asia Heart Hospital

Conditions

Atrial FibrillationPercutaneous Coronary InterventionStrokes Thrombotic

Phase 3

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

CompletedNCT02164864

Boehringer IngelheimAtrial Fibrillation, Percutaneous Coronary Intervention

Start: 2014-07-22End: 2017-06-05Updated: 2018-07-31

Unknown Phase

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

CompletedNCT03280641

Wuhan Asia Heart HospitalAtrial Fibrillation, Strokes Thrombotic

Start: 2015-08-09End: 2017-09-01Updated: 2017-09-12

Related Papers

Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial

Drugs2020-06-1917 citations

Comparison of Dabigatran Plus a P2Y<sub>12</sub> Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.

2020-05-075 citations

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2020-04-0124 citations

P34 The effect of sex on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial

European Heart Journal2020-01-01

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.

2019-08-019 citations

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

New England Journal of Medicine2017-08-271323 citations